Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheng Bin

Showing results (201-210 of 206) with videos related to

Pageof 21
Sort By:
You have reached the last page of results.This site can display upto 206 results.
Molecular Cancer Therapeutics|November 21, 2019
ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision MedicineShripad V Bhagwat, William T McMillen, Shufen Cai, et al.
Cell Reports|June 20, 2020
Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant CancersIrem Ozkan-Dagliyan, J Nathaniel Diehl, Samuel D George, et al.
Microbiology Spectrum|September 12, 2022
Sequence Type 5 (ST5) as a Possible Predictor of Bacterial Persistence in Adult Patients with Methicillin-Resistant Staphylococcus aureus Pneumonia Treated with VancomycinYa-Xin Fan, Meng-Ting Chen, Nan-Yang Li, et al.
Cancer Cell|September 8, 2015
Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant CancersSheng-Bin Peng, James R Henry, Michael D Kaufman, et al.
Cancer Research|December 9, 2024
Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast CancerShripad V Bhagwat, Cecilia Mur, Matthew Vandekopple, et al.
Journal of Medicinal Chemistry|May 13, 2015
Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cellsJames R Henry, Michael D Kaufman, Sheng-Bin Peng, et al.
Pageof 21

Showing results (201-210 of 206) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 206 results.
Molecular Cancer Therapeutics|November 21, 2019
ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision MedicineShripad V Bhagwat, William T McMillen, Shufen Cai, et al.
Cell Reports|June 20, 2020
Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant CancersIrem Ozkan-Dagliyan, J Nathaniel Diehl, Samuel D George, et al.
Microbiology Spectrum|September 12, 2022
Sequence Type 5 (ST5) as a Possible Predictor of Bacterial Persistence in Adult Patients with Methicillin-Resistant Staphylococcus aureus Pneumonia Treated with VancomycinYa-Xin Fan, Meng-Ting Chen, Nan-Yang Li, et al.
Cancer Cell|September 8, 2015
Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant CancersSheng-Bin Peng, James R Henry, Michael D Kaufman, et al.
Cancer Research|December 9, 2024
Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast CancerShripad V Bhagwat, Cecilia Mur, Matthew Vandekopple, et al.
Journal of Medicinal Chemistry|May 13, 2015
Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cellsJames R Henry, Michael D Kaufman, Sheng-Bin Peng, et al.
Pageof 21